Autopsy report · NCT00668785

Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

“Study was terminated due to low enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month after it had already started.
• Ran for about 5 years before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 3 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Jumper, J. Michael, M.D.

Sponsor type

University, hospital or other

Conditions

Proliferative Diabetic Retinopathy; Macular Edema

Interventions

ranibizumab

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
  “Study was terminated due to poor enrollment” (97% match in meaning)
• Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
  “Study terminated due to low enrollment.” (97% match in meaning)
• Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
  “The study was terminated due to low enrollment” (97% match in meaning)
• Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
  “The study is terminated due to lower enrollment” (95% match in meaning)
• Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
  “the study was terminated early due to poor enrollment” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.